Purchase this article with an account.
T. Suzuki, K. Kawai; The Effects of Topical Dorzolamide on Preventing Macular Edema After Vitrectomy. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4721.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of a topical carbonic anhydrase inhibitor on macular edema after vitrectomy.
20 patients after vitrectomy for epiretinal membranes were included in this study. 10 eyes of 20 patients received topical 2% dorzolamide, three times a day. The patients were followed-up for 3 months at least. In this study, the effect of dorzolamide on visual acuity (VA), intraocular pressure and central macular thickness (CMT) was evaluated.
Mean VA at the preoperation, and 2 weeks, 1 and 3 months after operation between the treatment group (0.33 (20/60.6), 0.25 (20/80), 0.40 (20/50), and 0.58 (20/34.5) ) and the control group (0.4 (20/50), 0.36 (20/55.6), 0.48 (20/41.7), and 0.68 (20/29.4) ) were not statistically significant. Mean CMT at 1 month after operation between the treatment group (358.8µm) and the control group (467.8µm) was statistically significant (p<0.05), but mean CMT at the preoperation, and 2 weeks and 3 months after operation between the treatment group (572.6, 427.2, and 333.4µm) and the control group (571.4, 485.2, and 388.4µm) were not statistically significant. Mean intraocular pressure at the preoperation, and at 2 weeks, 1 and 3 months after operation between the treatment group and the control group were not statistically significant, and intraocular pressure never exceeded 21mmHg.
Topical dorzolamide significantly reduced mean CMT at 1 month after operation for epiretinal membranes compared with control. Although further investigation on more cases and longer follow-up are needed, this study suggests that a topical dorzolamide can be efficacious in reducing macular edema in the early phase of post-vitrectomy.
This PDF is available to Subscribers Only